Alpha Centric Advisors LLC Neurocrine Biosciences Inc Transaction History
Alpha Centric Advisors LLC
- $97.4 Million
- Q4 2024
A detailed history of Alpha Centric Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 3,684 shares of NBIX stock, worth $416,697. This represents 0.52% of its overall portfolio holdings.
Number of Shares
3,684
Previous 22,500
83.63%
Holding current value
$416,697
Previous $2.59 Million
80.62%
% of portfolio
0.52%
Previous 2.19%
Shares
11 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.61 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.14 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$553 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$341 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$287 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...